Skip to Main Content

Paper Details

Comparative Pharmacokinetics of Tixagevimab/Cilgavimab (AZD7442) Administered Intravenously Versus Intramuscularly in Symptomatic SARS-CoV-2 Infection.
Clin Pharmacol Ther
8
2022
AZD1061, AZD7442, AZD8895, COVID-19, Cilgavimab, Evusheld, Participants, SARS-CoV-2, SARS-CoV-2 Infection, Tixagevimab, Women, anti-, cilgavimab, human, men, participants, severe acute respiratory syndrome, severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) monoclonal antibodies, tixagevimab
Author NameAffiliation
David A WohlInstitute of Global Health and Infectious Diseases, University of North Carolina at Chapel Hill
Joseph J EronInstitute of Global Health and Infectious Diseases, University of North Carolina at Chapel Hill
Judith S CurrierDavid Geffen School of Medicine at University of California Los Angeles
Judith S CurrierDavid Geffen School of Medicine at University of California Los Angeles
Davey M SmithUniversity of California - San Diego
  • 1 - 5

Datasets

Release 1.2